What is HC Wainwright’s Forecast for SPRB Q1 Earnings?

Spruce Biosciences, Inc. (NASDAQ:SPRB) – Research analysts at HC Wainwright issued their Q1 2027 earnings estimates for Spruce Biosciences in a report issued on Monday, June 1st. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($3.92) for the quarter. HC Wainwright has a “Buy” rating and a $150.00 price objective on the stock. The consensus estimate for Spruce Biosciences’ current full-year earnings is ($27.49) per share. HC Wainwright also issued estimates for Spruce Biosciences’ Q2 2027 earnings at ($3.58) EPS, Q3 2027 earnings at ($2.26) EPS and Q4 2027 earnings at $0.61 EPS.

Spruce Biosciences (NASDAQ:SPRB) last posted its earnings results on Wednesday, May 13th. The company reported ($8.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($7.93) by ($1.01).

Other research analysts have also recently issued research reports about the stock. Craig Hallum began coverage on shares of Spruce Biosciences in a research note on Monday, April 27th. They issued a “buy” rating and a $140.00 target price for the company. Citizens Jmp cut their target price on shares of Spruce Biosciences from $170.00 to $150.00 and set a “market outperform” rating for the company in a research note on Thursday, May 14th. Finally, Oppenheimer reiterated an “outperform” rating on shares of Spruce Biosciences in a research note on Wednesday, May 27th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $176.60.

Spruce Biosciences Stock Performance

NASDAQ:SPRB opened at $50.70 on Tuesday. Spruce Biosciences has a 1 year low of $4.35 and a 1 year high of $240.00. The firm has a 50 day moving average of $59.11 and a 200-day moving average of $71.89. The company has a current ratio of 4.67, a quick ratio of 4.67 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $139.53 million, a P/E ratio of -1.39 and a beta of 3.26.

Institutional Trading of Spruce Biosciences

A number of institutional investors have recently bought and sold shares of SPRB. Carlyle Group Inc. acquired a new stake in Spruce Biosciences during the 3rd quarter worth $24,765,000. Cable Car Capital LP acquired a new stake in Spruce Biosciences during the 3rd quarter worth $239,000. Geode Capital Management LLC acquired a new stake in Spruce Biosciences during the 4th quarter worth $1,109,000. State Street Corp acquired a new stake in Spruce Biosciences during the 4th quarter worth $558,000. Finally, Alyeska Investment Group L.P. acquired a new stake in Spruce Biosciences during the 4th quarter worth $4,501,000. Institutional investors and hedge funds own 91.71% of the company’s stock.

Spruce Biosciences Company Profile

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.